Effect of patient-led cooperative follow-up by general practitioners and community pharmacists on osteoporosis treatment persistence
© 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd..
AIM: Osteoporosis is a major risk factor for fractures. Poor persistence with osteoporosis medication hampers outcomes. This study assessed whether encouraging the formation of patient-led follow-up cooperatives between general practitioners (GPs) and community pharmacists improved medication persistence.
METHODS: All consecutive patients who attended an osteoporosis patient education program were invited to participate. They were given a logbook containing questionnaires they would bring to 6-monthly visits to their GP and pharmacist. The effect of this 3-year cooperative follow-up on persistence with medication and lifestyle changes was assessed.
RESULTS: In total, 121 patients (average age, 67 years; 93% female) participated. Poor cooperation between GPs and pharmacists was noted. Nevertheless, medication persistence ranged from 83% to 91% over the 6 visits. However, since patient drop-out rates were high and questionnaire return rates were low, a post-study medical chart review was performed. This confirmed that persistence was high (74%-83%) at 3 years post-enrollment, even for oral bisphosphonate-treated patients (73%-76%). However, adoption of anti-osteoporosis lifestyle changes was poor throughout the study: one- to two-thirds of the patients did not alter their diet, physical activity, or surroundings to prevent falls.
CONCLUSION: One study goal, namely, to encourage GPs and pharmacists to cooperate in patient follow-up, was not achieved. However, high medication persistence was observed. This may reflect the education program, patient empowerment, personalized attention from study personnel, and being in a study. Patient-centered approaches can thus significantly increase medication persistence in osteoporosis. Ongoing education may be needed to improve patient adoption of and persistence with lifestyle changes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
International journal of rheumatic diseases - 24(2021), 7 vom: 02. Juli, Seite 912-921 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Poivret, Didier [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bone Density Conservation Agents |
|---|
| Anmerkungen: |
Date Completed 08.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1756-185X.14146 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326066934 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326066934 | ||
| 003 | DE-627 | ||
| 005 | 20231225193803.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1756-185X.14146 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM326066934 | ||
| 035 | |a (NLM)34058072 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poivret, Didier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of patient-led cooperative follow-up by general practitioners and community pharmacists on osteoporosis treatment persistence |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a AIM: Osteoporosis is a major risk factor for fractures. Poor persistence with osteoporosis medication hampers outcomes. This study assessed whether encouraging the formation of patient-led follow-up cooperatives between general practitioners (GPs) and community pharmacists improved medication persistence | ||
| 520 | |a METHODS: All consecutive patients who attended an osteoporosis patient education program were invited to participate. They were given a logbook containing questionnaires they would bring to 6-monthly visits to their GP and pharmacist. The effect of this 3-year cooperative follow-up on persistence with medication and lifestyle changes was assessed | ||
| 520 | |a RESULTS: In total, 121 patients (average age, 67 years; 93% female) participated. Poor cooperation between GPs and pharmacists was noted. Nevertheless, medication persistence ranged from 83% to 91% over the 6 visits. However, since patient drop-out rates were high and questionnaire return rates were low, a post-study medical chart review was performed. This confirmed that persistence was high (74%-83%) at 3 years post-enrollment, even for oral bisphosphonate-treated patients (73%-76%). However, adoption of anti-osteoporosis lifestyle changes was poor throughout the study: one- to two-thirds of the patients did not alter their diet, physical activity, or surroundings to prevent falls | ||
| 520 | |a CONCLUSION: One study goal, namely, to encourage GPs and pharmacists to cooperate in patient follow-up, was not achieved. However, high medication persistence was observed. This may reflect the education program, patient empowerment, personalized attention from study personnel, and being in a study. Patient-centered approaches can thus significantly increase medication persistence in osteoporosis. Ongoing education may be needed to improve patient adoption of and persistence with lifestyle changes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a inter-professional cooperation | |
| 650 | 4 | |a lifestyle changes | |
| 650 | 4 | |a osteoporosis | |
| 650 | 4 | |a patient empowerment | |
| 650 | 4 | |a persistence | |
| 650 | 7 | |a Bone Density Conservation Agents |2 NLM | |
| 650 | 7 | |a Diphosphonates |2 NLM | |
| 700 | 1 | |a Goetz, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Zevering, Yinka |e verfasserin |4 aut | |
| 700 | 1 | |a Wilcke, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Noirez, Véronique |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of rheumatic diseases |d 2009 |g 24(2021), 7 vom: 02. Juli, Seite 912-921 |w (DE-627)NLM197180566 |x 1756-185X |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2021 |g number:7 |g day:02 |g month:07 |g pages:912-921 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1756-185X.14146 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2021 |e 7 |b 02 |c 07 |h 912-921 | ||